Infinity Pharmaceuticals, Inc.

Informe acción OTCPK:INFI.Q

Capitalización de mercado: US$90.0

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Infinity Pharmaceuticals Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Seth Tasker

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEO7.7yrs
Participación del CEOn/a
Permanencia media de la direcciónsin datos
Promedio de permanencia en la Junta Directiva6yrs

Actualizaciones recientes de la dirección

Artículo de análisis • Jun 03

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Performance at Infinity Pharmaceuticals, Inc. ( NASDAQ:INFI ) has been reasonably good and CEO Adelene Perkins has done...

Recent updates

Artículo de análisis • Nov 10

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Sep 08

Infinity Pharmaceuticals: Waiting For A Deal

Summary Today, we revisit small oncology concern Infinity Pharmaceuticals for the first time in 2022. The company's primary drug Eganelisib has shown encouraging results as part of combination therapies, but the company is waiting on a collaboration deal to move development forward. Is a key strategic partnership worth the wait? An investment analysis follows in the paragraphs below. A man might share his wealth, but never his authority. - Amit Kalantri We concluded our last piece on Infinity Pharmaceuticals (INFI) in November 2021 saying it probably merited a small 'watch item' holding, preferably with a covered call position. Today, we follow up and see how this small biotech firm is progressing. An analysis follows below. Seeking Alpha Company Overview: Infinity Pharmaceuticals is headquartered in Cambridge, MA and its main focus continues to be developing novel medicines to treat cancer. This small oncology firm has a market cap of approximately $135 million and the stock trades near $1.50 a share. Pipeline: The company's core focus continues to be to develop its primary drug candidate Eganelisib as part of combination therapies to treat a variety of oncology indications. Eganelisib is a first-in-class, oral, once-daily, immuno-oncology (I/O) development candidate selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma). According to the company's website, Eganelisib works by: May Company Presentation Reprogramming key immune suppressive cells (called M2 macrophages or myeloid derived suppressor cells (MDSCs)) within the tumor microenvironment from a pro-tumor function to an anti-tumor function, decreasing immune suppression and increasing immune activation, ultimately leading to the activation and proliferation of T cells that can attack cancer cells. Company Website Since our last update around Infinity Pharmaceuticals, the company has disclosed some trial results. In December of last year, Infinity posted some updated data from its ongoing MARIO-3 study. This Phase 2 trial was designed to evaluate Eganelisib in combination with Roche's (RHHBY) atezolizumab (Tecentriq) and chemotherapy nab-paclitaxel (Abraxane) in frontline metastatic triple-negative breast cancer (TNBC). According to the lead scientist on the results showed 'Tumor reductions in 88.6% of evaluable patients were associated with a disease control rate of 81.4% in patients with PD-L1 negative tumors who are among the most challenging to treat'. The company should review updated PFS data from this study by the end of this year. Company Presentation Then a month ago, the company posted data from its two-year analysis of its phase 2 MARIO-275 study. This trial is evaluating Eganelisib in combination with Bristol-Myers' (BMY) Opdivo for the treatment of second line urothelial cancer. A key conclusion of the analysis was that 45% of patients in the Eganelisib combination treatment arm were alive compared to 24% of patients in just the Opdivo arm. In addition, this improvement was also seen in the PD-L1 negative tumor subgroup, with 38% of those patients alive at two years on the Eganelisib plus Opdivo arm versus only 17% on the Opdivo arm. These encouraging results are the key factor behind the recent rally in the stock. The only other active study is MARIO-1, which is in a far earlier stage of development, so is not germane to this analysis. Analyst Commentary & Balance Sheet: Over the past six months, five analyst firms including Piper Sandler and Oppenheimer have reissued Buy ratings on the stock. Albeit, three of these contain downward price target revisions. Price targets proffered range from $3 to $9 a share. JonesTrading maintained its Hold rating on INFI on August 12th.
Artículo de análisis • May 23

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Artículo de análisis • Dec 29

We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Nov 25

Investigating Infinity Pharmaceuticals

Today we tee up a small 'off the radar' oncology concern called Infinity Pharmaceuticals for some in-depth research. The company posted encouraging trial results in July and is working with large drug makers to establish its primary candidate as part of combo therapies. A full investment analysis follows in the paragraphs below.
Artículo de análisis • Jul 18

Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Jun 03

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Performance at Infinity Pharmaceuticals, Inc. ( NASDAQ:INFI ) has been reasonably good and CEO Adelene Perkins has done...
Artículo de análisis • Apr 13

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Infinity...
Artículo de análisis • Feb 19

Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?

If you want to know who really controls Infinity Pharmaceuticals, Inc. ( NASDAQ:INFI ), then you'll have to look at the...
Artículo de análisis • Jan 15

Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?

Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right stock, you can make a...
Artículo de análisis • Dec 11

Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Seth Tasker en comparación con los beneficios de Infinity Pharmaceuticals?
FechaCompensación totalSalarioIngresos de la empresa
Jun 30 2023n/an/a

-US$41m

Mar 31 2023n/an/a

-US$43m

Dec 31 2022n/an/a

-US$44m

Sep 30 2022n/an/a

-US$47m

Jun 30 2022n/an/a

-US$47m

Mar 31 2022n/an/a

-US$46m

Dec 31 2021n/an/a

-US$45m

Sep 30 2021n/an/a

-US$44m

Jun 30 2021n/an/a

-US$43m

Mar 31 2021n/an/a

-US$41m

Dec 31 2020US$1mUS$386k

-US$40m

Sep 30 2020n/an/a

-US$41m

Jun 30 2020n/an/a

-US$43m

Mar 31 2020n/an/a

-US$44m

Dec 31 2019US$653kUS$368k

-US$47m

Sep 30 2019n/an/a

-US$44m

Jun 30 2019n/an/a

-US$19m

Mar 31 2019n/an/a

-US$16m

Dec 31 2018n/an/a

-US$11m

Sep 30 2018n/an/a

-US$10m

Jun 30 2018n/an/a

-US$31m

Mar 31 2018n/an/a

-US$41m

Dec 31 2017US$1mUS$320k

-US$42m

Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Seth es razonable en comparación con empresas de tamaño similar en el mercado US.

Compensación vs. Ingresos: La compensación de Seth ha aumentado mientras la empresa no es rentable.

CEO

Seth Tasker (44 yo)

7.7yrs
Permanencia
US$1,435,444
Compensación

Mr. Seth A. Tasker, J.D., has been Senior Vice President, General Counsel and Secretary at Infinity Pharmaceuticals, Inc. since December 2019 and has been its CEO since September 1, 2023 and had been its C...

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Anthony Evnin
Independent Director17.5yrsUS$93.08k0.24%
$ 0.2
Norman Selby
Lead Independent Director12yrsUS$125.82k0.017%
$ 0.01
David Beier
Independent Director5.9yrsUS$85.58k0.0097%
$ 0.009
Roy Steven Herbst
Member of Scientific Advisory Board6yrssin datossin datos
David Munn
Member of Scientific Advisory Board6yrssin datossin datos
F. Hodi
Member of Scientific Advisory Board6yrssin datossin datos
Richard B. Gaynor
Independent Director4yrsUS$83.08k0%
$ 0
Dmitry Gabrilovich
Member of Scientific Advisory Board6yrssin datossin datos
Jeffery Kutok
Chairman of Scientific Advisory Board4yrsUS$759.67ksin datos
Samuel Agresta
Chair of Clinical Advisory Boardno dataUS$73.08k0.012%
$ 0.01
Toni Choueiri
Member of Clinical Advisory Boardno datasin datossin datos
Michael Postow
Member of Clinical Advisory Boardno datasin datossin datos
6.0yrs
Permanencia media
71yo
Promedio de edad

Junta con experiencia: La junta directiva de INFI.Q se considera experimentada (6 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2024/03/11 16:00
Precio de las acciones al final del día2024/03/11 00:00
Beneficios2023/06/30
Ingresos anuales2022/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Infinity Pharmaceuticals, Inc. está cubierta por 23 analistas. de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Christopher RaymondBaird
Andrew D'SilvaB. Riley Securities, Inc.
Michael KingCitizens JMP Securities, LLC